Severino Pimentel, MD
Family Medicine · Katy, TXNPI 1003844820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $699 and has fallen 50.2% since, to $348 in 2025.
Across 185 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$505
- AbbVie$502
- Nestle Healthcare Nutrition Inc.$342
- GSK$310
- Lilly USA, LLC$273
- Amarin Pharma, Inc.$210
- plus $1K from 22 others
Across 8 payments — averaging $2405.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$19K
- Janssen Research & Development, LLC$500
What the payments were for
- Food & beverage$3,258100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $505 |
| AbbVie(2 entities) | 39 | $502 |
| Nestle Healthcare Nutrition Inc. | 15 | $342 |
| GSK | 15 | $310 |
| Lilly USA, LLC | 17 | $273 |
| Amarin Pharma, Inc. | 12 | $210 |
| Antares Pharma, Inc. | 10 | $199 |
| Eisai Inc. | 5 | $118 |
| Aimmune Therapeutics, Inc. | 6 | $110 |
| AstraZeneca | 5 | $98 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Vivus LLC | 3 | $68 |
| Endo Pharmaceuticals Inc. | 3 | $50 |
| Genentech USA, Inc. | 2 | $46 |
| Althera Pharmaceuticals LLC | 2 | $44 |
| Amgen | 3 | $41 |
| Bausch Health US, LLC | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Johnson & Johnson | 2 | $28 |
| Merck | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Pfizer | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Abbott | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$3,272 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 251 | $314,360 |
| MounjaroTirzepatide | 103 | $131,786 |
| Humira PenAdalimumab | 13 | $103,009 |
| EliquisApixaban | 60 | $49,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $34,720 |
| ZenpepLipase/Protease/Amylase | 17 | $31,640 |
| ProliaDenosumab | 12 | $20,793 |
| VascepaIcosapent Ethyl | 27 | $20,421 |
| XareltoRivaroxaban | 20 | $19,376 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $16,386 |
| Icosapent Ethyl | 32 | $15,691 |
| FarxigaDapagliflozin Propanediol | 13 | $13,171 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $12,757 |
| GemtesaVibegron | 16 | $6,499 |
| Rosuvastatin Calcium | 490 | $6,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $505 | $314,360251 claims |
| Lilly USA, LLCMounjaro | $273 | $131,786103 claims |
| PfizerEliquis | $23 | $49,50660 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $310 | $40,16849 claims |
| Aimmune Therapeutics, Inc.Zenpep | $110 | $31,64017 claims |
| AstraZenecaFarxiga, Symbicort | $98 | $25,92840 claims |
| AmgenProlia | $41 | $20,79312 claims |
| Johnson & JohnsonXarelto | $28 | $19,37620 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $29 | $16,38615 claims |
| AbbVieSynthroid | $502 | $2,60848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Katy
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.